MBH acted as Egyptian counsel to Acino in the acquisition of prescription and OTC products from Takeda Pharmaceuticals

IFLR is part of Legal Benchmarking Limited, 1-2 Paris Garden, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement


MBH acted as Egyptian counsel to Acino in the acquisition of prescription and OTC products from Takeda Pharmaceuticals

Sponsored by

23MatoukBassiouny.png

MBH acted as Egyptian counsel to Acino in the acquisition of prescription and OTC products from Takeda Pharmaceuticals

Matouk Bassiouny & Hennawy (“MBH”) acted as Egyptian counsel to Acino, a Swiss pharmaceutical company, with Latham & Watkins as international counsel, in the acquisition of selected prescription and over-the-counter assets from Takeda pharmaceuticals, a multinational pharmaceutical company headquartered in Japan. The deal is valued at an excess of USD 200 million and closing was announced on 2 March 2020.

The MBH team assisting on the transaction was led by Omar S. Bassiouny (Founding Partner and Head of Corporate and M&A) and Muhammad Nassef (Partner), and included Khalid Al-Melegi (Associate) and Lina Raouf (Junior Associate).

Gift this article